Motilal Oswal has projected an annual revenue growth of over 15% for Emcure Pharmaceuticals through 2028. The firm highlights a recovery in domestic market share and strong international demand as primary growth drivers. With the stock currently trading at 21 times forward earnings, investors are tracking if the company can sustain this performance against intense industry competition.
Motilal Oswal Financial Services has released a research note projecting a growth phase for Emcure Pharmaceuticals. The brokerage firm set a 12-month forward price target of Rs 2,330 for the stock, citing a revenue growth rate of 15.2% annually expected between fiscal years 2026 and 2028. This outlook is built on a strategy of expanding both domestic and international operations.
The brokerage expects international business to grow at a 17.4% annual rate, while domestic formulations are projected to expand at 12.4%. A key factor in this positive outlook is the recent improvement in domestic market performance. In September 2026, Emcure Pharmaceuticals reported 19.3% year-over-year growth, which outpaced the broader Indian pharmaceutical market growth of 17.1% by 220 basis points. This marks a notable change from the previous year, during which the company had struggled to match industry benchmarks.
The brokerage calculates this target based on a 28 times multiple of the company's forward earnings. With the stock recently trading around 21 times its 12-month forward price-to-earnings ratio, analysts view this as a potential point of interest for market observers.
However, investors should consider the broader environment in which pharmaceutical companies operate. Success in this sector is highly dependent on effective product launches, steady demand in key therapy areas, and efficient manufacturing capabilities. Like many of its peers, Emcure Pharmaceuticals remains subject to strict regulatory scrutiny. Any adverse findings by regulators such as the US FDA, or challenges in the global supply chain, could affect the company’s ability to meet its growth targets.
Furthermore, the pharmaceutical industry is intensely competitive. While the company has shown a recovery in growth, maintaining this lead over the industry average requires consistent performance in highly regulated markets. Investors should monitor the company’s quarterly results for signs of sustained profit margin expansion and successful execution of its international strategy. Tracking any updates on new drug approvals and the status of manufacturing facilities will also be important for evaluating future progress.